Dr. Avery Posey headshotDr. Posey of the University of Pennsylvania is developing a novel CAR-T cell therapy that selectively targets an antigen found only in neuroblastoma called PolySia.

In 2015, unituxin (anti-GD2 antibody), was approved for treatment of NB patients and currently shows a 20% increase in event free survival over standard of care CAR-T cell therapy has shown success in pediatric ALL, but CAR-T cells targeting GD2 may have significant adverse effects.

He will design and develop a PolySia CAR-T for use in neuroblastoma patients. He will then test the anti-tumor effects and safety of the PolySia CAR-T therapy in mouse models of neuroblastoma. His goal is to translate this work to pediatric clinical trials within three to four years and initiate pediatric clinical trials.

Pin It on Pinterest

Scroll to Top